Questions aim low, answers land high: the dialogue keeps correcting expectations upward with facts already in hand
The model's full reasoning — Q4 2017 call → NOWe need answer YES/NO. Need analyze transcript for mismatch in level: analysts cautious/below, management corrects upward with concrete already happening. Need determine if recurring across call. Let's examine Q&A. First question Randall Stanicky: guidance implies growth 8% vs low double-digit growth seen in Dec/Jan. "where is disconnect?" and J&J ramp. Also J code timeline and what boost. Management: guidance conservative, moving parts, J&J partnership great, CMS discussions constructive, material opportunity. This is management correcting upward? Analyst questions about guidance being low vs recent growth, actually analyst is questioning why guidance lower than recent strength. That's not below business; it's asking management to explain conservative guidance. Management says conservative, upside. But not necessarily concrete already happening? They cite J&J, CMS discussions. Hmm. Second Doug Tsao: breakdown ortho vs soft tissue, traction. Management says data lags, everything growing, ortho >50%, TAP growing, J&J spine etc. Analyst not necessarily cautious? Neutral. Third Tazeen: pipeline, chronic pain, generic entrants. Management corrects DepoMeloxicam vs Tranexamic, chronic pain interest, generic guidance positive. Not mismatch upward? Analyst asks about pipeline, generic risk. Management says generic high hurdle. Could be upward correction but not recurring. Fourth Mickey: nerve block off-label usage, AdCom re-evaluate R&D. Management says single-digit, open dialogue. Not upward. Fifth Dana: opioid-sparing claims guidance. Management says not in discussion, don't hold breath. That's actually management dampening? Analyst asks if FDA guidance could impact; management says no. Not upward. Sixth Chris Schott: Phase 4 programs, read across from AdCom, largest opportunities. Management gives long answer about opportunities, but not correcting cautious premise? Analyst asks about design and timing. Management says all on label, no FDA interaction. Could be upward. Seventh Serge: Trinity collaboration driver, Aetna oral health. Management says progress, Aetna CMO testimony, other relationships. Analyst asks how much driver; management positive with concrete. But analyst not necessarily below? Maybe. Eighth Gary: sales force transition, nerve block delay, spray process. Management says not abandoned orthopedics, manufacturing details.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| FWONK | Formula One Group | Q1 2024 | 2024-05-08 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| EGP | EastGroup Properties, Inc. | Q4 2023 | 2024-02-08 | B |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| ADM | Archer-Daniels-Midland Company | Q4 2022 | 2023-01-26 | C+ |
| HBAN | Huntington Bancshares Incorporated | Q4 2022 | 2023-01-20 | B |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| ICL | ICL Group Ltd | Q3 2022 | 2022-11-09 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| HLNE | Hamilton Lane Incorporated | Q1 2023 | 2022-08-02 | C+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| PRGS | Progress Software Corporation | Q2 2022 | 2022-06-28 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| BHF | Brighthouse Financial, Inc. | Q1 2022 | 2022-05-10 | C |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| STM | STMicroelectronics NV | Q3 2018 | 2018-10-24 | C+ |
| TMHC | Taylor Morrison Home Corporation | Q2 2018 | 2018-08-01 | B |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| LAUR | Laureate Education, Inc. | Q1 2018 | 2018-05-13 | B+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| KRG | Kite Realty Group Trust | Q1 2018 | 2018-04-26 | C+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SNA | Snap-on Incorporated | Q3 2017 | 2017-10-19 | B |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DHR | Danaher Corporation | Q1 2017 | 2017-04-20 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| JHX | James Hardie Industries plc | Q3 2016 | 2016-02-19 | B+ |
GOGO · Q1 2016 → YESThe question is about whether there's a clear, recurring mismatch where analysts assume a more modest/cautious/troubled version, and management corrects UPWARD with things already happening. YES The analysts' questions repeatedly frame the business around cautious or risk-oriented assumptions—such as ARPA trajectory concerns amid competition, cash and liquidity needs, potential sentiment issues with the Gogo brand, and competitive pressures from Panasonic—while management consistently corrects upward by citing concrete, already-realized facts: record revenues, 2Ku now in service on AeroMexico and IAG, over 1,000 planes awarded, Delta increases, install records, and backlog progress already achieved. This pattern repeats across multiple exchanges, with management pointing to present-tense operational realities that exceed the cautious premises embedded in the questions.
LAUR · Q1 2018 → YESThe question is about whether there's a clear, recurring mismatch in level between what the questioners assume and what management reports, with the mismatch running UPWARD. Analysts think more modest...YES The transcript shows a clear recurring mismatch running upward. Analysts repeatedly probe cautious angles—Chile as a potential end rather than final ruling, Brazil FIES exposure as a risk, margin phasing and guidance including divestitures, Turkey as needing update, FCF not raised despite Chile, leverage post-St. Augustine, and Accelerator 2.0 health sciences—framing the business around lingering uncertainties or modest upside.
JHX · Q3 2016 → YESThe question is about whether there's a clear, recurring mismatch where analysts assume a more modest/cautious/troubled version, and management corrects UPWARD with concrete things already happening. ...NO The transcript shows analysts probing for signs of weakness or slowdowns (seasonal margins, destocking, Europe performance, PDG pickup, volumes vs targets), but management repeatedly corrects upward with concrete current facts: strong Q3 margins (2.6 points better), no destocking, plants running well, costs controlled, 12% volume growth, Europe already through the one-off, and inventory normalized.